SG10201805674YA - Determinants of cancer response to immunotherapy - Google Patents
Determinants of cancer response to immunotherapyInfo
- Publication number
- SG10201805674YA SG10201805674YA SG10201805674YA SG10201805674YA SG10201805674YA SG 10201805674Y A SG10201805674Y A SG 10201805674YA SG 10201805674Y A SG10201805674Y A SG 10201805674YA SG 10201805674Y A SG10201805674Y A SG 10201805674YA SG 10201805674Y A SG10201805674Y A SG 10201805674YA
- Authority
- SG
- Singapore
- Prior art keywords
- immunotherapy
- cancer
- determinants
- response
- neoepitopes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy. The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy can be predicted. The present invention further comprises the discovery that cancer cells may harbor somatic mutations that result in neoepitopes that are recognizable by a patient's immune system as non-self. The identification of one or more neoepitopes in a cancer sample is useful for determining which cancer patients are likely to respond favorably to immunotherapy, in particular, treatment with an immune checkpoint modulator. [FIG. 1]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461923183P | 2014-01-02 | 2014-01-02 | |
US201462066034P | 2014-10-20 | 2014-10-20 | |
US201462072893P | 2014-10-30 | 2014-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201805674YA true SG10201805674YA (en) | 2018-08-30 |
Family
ID=53494217
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201805674YA SG10201805674YA (en) | 2014-01-02 | 2014-12-23 | Determinants of cancer response to immunotherapy |
SG11201605432RA SG11201605432RA (en) | 2014-01-02 | 2014-12-23 | Determinants of cancer response to immunotherapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605432RA SG11201605432RA (en) | 2014-01-02 | 2014-12-23 | Determinants of cancer response to immunotherapy |
Country Status (15)
Country | Link |
---|---|
US (1) | US20160326597A1 (en) |
EP (1) | EP3090066A4 (en) |
JP (1) | JP2017504324A (en) |
KR (1) | KR20160102314A (en) |
CN (1) | CN106164289A (en) |
AU (1) | AU2014374020A1 (en) |
BR (1) | BR112016015399A2 (en) |
CA (1) | CA2935214A1 (en) |
CL (1) | CL2016001708A1 (en) |
MX (1) | MX2016008771A (en) |
PE (1) | PE20161344A1 (en) |
PH (1) | PH12016501329A1 (en) |
RU (1) | RU2707530C2 (en) |
SG (2) | SG10201805674YA (en) |
WO (1) | WO2015103037A2 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
JP2017537087A (en) | 2014-11-13 | 2017-12-14 | ザ ジョンズ ホプキンス ユニバーシティー | Checkpoint interruption and microsatellite instability |
MA40737A (en) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY |
WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
CA2987730C (en) | 2015-04-08 | 2020-02-18 | Nantomics, Llc | Cancer neoepitopes |
CA2988388C (en) * | 2015-04-23 | 2022-11-22 | Nantomics, Llc | Cancer neoepitopes |
EP3294324A1 (en) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
EP3362929B1 (en) * | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
EP3362930A4 (en) * | 2015-10-12 | 2019-06-19 | Nantomics, LLC | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
IL258688B2 (en) * | 2015-10-12 | 2023-04-01 | Nantomics Llc | Compositions and methods for viral cancer neoepitopes |
WO2017070581A1 (en) * | 2015-10-23 | 2017-04-27 | Novartis Ag | Method of deriving a value for percent biomarker positivity for selected cells present in a field of view |
TWI733719B (en) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ip有限責任公司 | Improved compositions and methods for viral delivery of neoepitopes and uses thereof |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Neoantigen identification, manufacture, and use |
CN108472350A (en) * | 2016-01-08 | 2018-08-31 | 瓦西博迪公司 | New epitope RNA cancer vaccines |
EP3417289B1 (en) | 2016-02-19 | 2020-12-23 | Nant Holdings IP, LLC | Methods of immunogenic modulation |
US11725247B2 (en) | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
CA3015528A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP3431595A4 (en) * | 2016-03-15 | 2019-11-20 | Repertoire Genesis Incorporation | Monitoring and diagnosis for immunotherapy, and design for therapeutic agent |
RU2769314C1 (en) * | 2016-03-16 | 2022-03-30 | Амаль Терапьютикс Са | Combination of an immune checkpoint modulator and a complex containing a cell-penetrating peptide, a cargo molecule, and a tlr peptide agonist, for application in medicine |
WO2017214575A1 (en) * | 2016-06-10 | 2017-12-14 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
WO2018005276A1 (en) * | 2016-06-29 | 2018-01-04 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
WO2018055060A1 (en) | 2016-09-21 | 2018-03-29 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
EP3516081A4 (en) * | 2016-09-23 | 2020-07-29 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
EP3523451A1 (en) * | 2016-10-06 | 2019-08-14 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
JP2020507557A (en) | 2016-12-01 | 2020-03-12 | ナントミクス,エルエルシー | Processing and presentation of tumor antigenicity |
US11480572B2 (en) | 2016-12-16 | 2022-10-25 | Nantbio, Inc. | Live cell imaging systems and methods to validate triggering of immune response |
US20190369096A1 (en) * | 2017-01-13 | 2019-12-05 | Nantbio, Inc. | Validation of neoepitope-based treatment |
CA3050109A1 (en) | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigens and uses thereof for treating cancer |
WO2018146128A1 (en) * | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy |
WO2018170329A1 (en) * | 2017-03-17 | 2018-09-20 | Nantomics, Llc | LIQUID BIOPSY FOR cfRNA |
WO2018183928A1 (en) * | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
JP2020522479A (en) | 2017-06-02 | 2020-07-30 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | Methods for making personalized cancer vaccines |
GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
CA3076894A1 (en) * | 2017-09-25 | 2019-03-28 | Memorial Sloan Kettering Cancer Center | Tumor mutational load and checkpoint immunotherapy |
EP3694532A4 (en) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
JP7421474B2 (en) | 2017-11-03 | 2024-01-24 | ガーダント ヘルス, インコーポレイテッド | Normalization of tumor gene mutation burden |
EP3707272A4 (en) * | 2017-11-09 | 2021-11-24 | The Trustees of The University of Pennsylvania | Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment |
AU2018373154A1 (en) | 2017-11-22 | 2020-07-02 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
KR20200093438A (en) * | 2017-12-01 | 2020-08-05 | 일루미나, 인코포레이티드 | Method and system for determining somatic mutant clonability |
CN108009400B (en) * | 2018-01-11 | 2018-07-06 | 至本医疗科技(上海)有限公司 | Full-length genome Tumor mutations load forecasting method, equipment and storage medium |
US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
KR20210005646A (en) | 2018-04-26 | 2021-01-14 | 아게누스 인코포레이티드 | Heat shock protein-binding peptide composition and method for use thereof |
CA3107983A1 (en) | 2018-07-23 | 2020-01-30 | Guardant Health, Inc. | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
WO2020047378A1 (en) | 2018-08-31 | 2020-03-05 | Guardant Health, Inc. | Microsatellite instability detection in cell-free dna |
CN109371005B (en) * | 2018-11-12 | 2022-09-30 | 上海市东方医院(同济大学附属东方医院) | HLA-0201 restrictive PADI4 epitope polypeptide and application thereof |
CN113194995A (en) * | 2018-12-12 | 2021-07-30 | 免疫医疗有限责任公司 | Predicting overall survival of non-small cell lung cancer based on tumor mutation burden of blood |
JP2022525487A (en) * | 2019-04-05 | 2022-05-17 | イルミナ インコーポレイテッド | Quantitative score of HLA diversity |
NL2024107B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Compositions for Patient Specific Immunotherapy |
CN111088349B (en) * | 2020-02-14 | 2023-04-28 | 深圳市宝安区妇幼保健院 | KIR3DL1 genotyping primer group and application thereof |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
WO2022217136A1 (en) * | 2021-04-10 | 2022-10-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A multiomic approach to modeling of gene regulatory networks in multiple myeloma |
CA3227081A1 (en) | 2021-08-24 | 2023-03-02 | Irena RABE | In vitro transcription technologies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
CN101072578A (en) * | 2004-10-29 | 2007-11-14 | 南加州大学 | Combination cancer immunotherapy with co-stimulatory molecules |
CA3197245A1 (en) * | 2010-05-14 | 2011-11-17 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
-
2014
- 2014-12-23 BR BR112016015399A patent/BR112016015399A2/en not_active IP Right Cessation
- 2014-12-23 JP JP2016544613A patent/JP2017504324A/en active Pending
- 2014-12-23 CN CN201480075287.2A patent/CN106164289A/en active Pending
- 2014-12-23 RU RU2016131207A patent/RU2707530C2/en not_active IP Right Cessation
- 2014-12-23 AU AU2014374020A patent/AU2014374020A1/en not_active Abandoned
- 2014-12-23 MX MX2016008771A patent/MX2016008771A/en unknown
- 2014-12-23 US US15/109,464 patent/US20160326597A1/en not_active Abandoned
- 2014-12-23 PE PE2016000989A patent/PE20161344A1/en unknown
- 2014-12-23 EP EP14876694.2A patent/EP3090066A4/en not_active Withdrawn
- 2014-12-23 KR KR1020167021093A patent/KR20160102314A/en not_active Application Discontinuation
- 2014-12-23 CA CA2935214A patent/CA2935214A1/en not_active Abandoned
- 2014-12-23 SG SG10201805674YA patent/SG10201805674YA/en unknown
- 2014-12-23 WO PCT/US2014/072125 patent/WO2015103037A2/en active Application Filing
- 2014-12-23 SG SG11201605432RA patent/SG11201605432RA/en unknown
-
2016
- 2016-07-01 CL CL2016001708A patent/CL2016001708A1/en unknown
- 2016-07-04 PH PH12016501329A patent/PH12016501329A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160102314A (en) | 2016-08-29 |
AU2014374020A1 (en) | 2016-08-18 |
PH12016501329A1 (en) | 2016-10-03 |
RU2707530C2 (en) | 2019-11-27 |
CL2016001708A1 (en) | 2017-03-17 |
EP3090066A2 (en) | 2016-11-09 |
RU2016131207A (en) | 2018-02-07 |
PE20161344A1 (en) | 2016-12-23 |
RU2016131207A3 (en) | 2018-06-22 |
SG11201605432RA (en) | 2016-07-28 |
WO2015103037A2 (en) | 2015-07-09 |
US20160326597A1 (en) | 2016-11-10 |
BR112016015399A2 (en) | 2017-10-24 |
JP2017504324A (en) | 2017-02-09 |
CN106164289A (en) | 2016-11-23 |
EP3090066A4 (en) | 2017-08-30 |
CA2935214A1 (en) | 2015-07-09 |
MX2016008771A (en) | 2016-12-20 |
WO2015103037A3 (en) | 2015-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501329A1 (en) | Determinants of cancer response to immunotherapy | |
JOP20200192A1 (en) | Anti-tigit antibodies | |
CY1122510T1 (en) | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
MX2017000116A (en) | Il-15-based molecules and methods of use thereof. | |
MX2021013586A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use. | |
WO2016081947A3 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
WO2015116868A3 (en) | Molecular profiling of immune modulators | |
NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
EP4007984A4 (en) | Self-sovereign identity systems and methods for identification documents | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
MX370807B (en) | Antibodies binding axl. | |
WO2016109782A3 (en) | Methods and compositions for detecting colorectal neoplasias | |
MY191539A (en) | Streptococcal vaccine | |
EP3209766A4 (en) | Tissue sample processing system and associated methods | |
MX2015014190A (en) | Covalently closed non-coding immunomodulatory dna construct. | |
FR3022664B1 (en) | AUTHENTICATION METHOD AND SYSTEM | |
EP3191121A4 (en) | Identification of immunologically protective neo-epitopes for the treatment of cancers | |
MA40636A (en) | Methods of detecting prostate cancer | |
IL248080A0 (en) | System and method of identifying sources associated with biological rhythm disorders | |
EP3234841A4 (en) | Computer-implemented system and method for identifying similar patients | |
EP3157680A4 (en) | Molecular analysis system and use thereof | |
WO2017095918A3 (en) | Methods for treating cancer using rspo3 antagonists | |
NZ728041A (en) | Substances and methods for the use in prevention and/or treatment in huntington’s disease | |
PLOS Neglected Tropical Diseases Staff | Correction: A Novel qPCR Assay for the Detection of African Animal Trypanosomosis in Trypanotolerant and Trypanosusceptible Cattle Breeds |